Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,922 recruiting studies in this area right now.
By phase
- Not applicable2,026
- Phase 21,073
- Phase 1790
- Phase 1/Phase 2479
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California395
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,922 total
- NCT05294055RecruitingPhase 2
Mecapegfilgrastim to help collect stem cells for transplant
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
Hefei, AnhuiAges 18–65 - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07111884Recruiting
Multiple myeloma registry study
This study collects information from multiple myeloma patients who previously took part in a GMMG therapy study. It helps researchers learn more about the disease and treatments over time.
BerlinAges 18 years+ - NCT07106736RecruitingPhase 2
CAR-T for newly diagnosed multiple myeloma without transplant
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07108868RecruitingPhase 1
Study of MB-CART2219.1 for blood cancers
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Tübingen, Baden-WurttembergAges 12–75 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07110090RecruitingPhase 1
Umbilical cord blood shot for low platelets after cancer treatment
This trial tests an injection made from umbilical cord blood to raise low platelet counts caused by cancer therapies like chemo, immunotherapy, or radiation. It may help people with mild to moderate low platelets who haven't had recent platelet transfusions or other platelet-raising drugs.
Beijing, Beijing MunicipalityAges 18–75 - NCT07112287Recruiting
Germline testing for myeloid cancer risk
This trial studies whether certain inherited genes increase the risk of myeloid cancers or bone marrow failure. You will provide a DNA sample via a skin biopsy to look for these genetic changes.
Boston, MassachusettsAges 18 years+ - NCT07114939RecruitingPhase 1
A new pet scan for pancreatic neuroendocrine tumors
This study is testing a special type of PET/CT scan using a tracer called FTT to see if it can better find and track pancreatic neuroendocrine tumors that have spread or cannot be removed by surgery. The goal is to improve imaging for people with this type of cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07106723RecruitingPhase 2
Study of stem cell transplant and CD7-CART for T-cell lymphoma
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106684RecruitingPhase 2
Stem cell transplant with car-t and bi-specific antibody for plasma cell leukemia
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106710RecruitingPhase 2
Stem cell transplant plus two targeted therapies for ultra-high-risk myeloma
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07111598Recruiting
Iron supplements and the immune system in HHT
This study looks at how iron supplements affect the immune system in people with HHT (a genetic condition that causes bleeding from abnormal blood vessels). You may be placed in one of three groups depending on your iron and ferritin levels.
Bron, RhoneAges 18–99 - NCT07108374Enrolling by invitation
Improving blood transfusion practices in children's ICUs
This study tests whether a new set of guidelines can help doctors and nurses give red blood cell transfusions more consistently in pediatric intensive care. It aims to make transfusion decisions safer and more uniform for children in the ICU.
Palo Alto, CaliforniaAges Any age - NCT07110987Recruiting
Adding a Medicine to Light Therapy for Newborn Jaundice
This study tests whether adding a medicine called Ursodeoxycholic Acid (UDCA) to standard light therapy (phototherapy) helps treat newborn jaundice more quickly. Jaundice causes yellow skin and eyes, and this trial looks at babies whose jaundice is severe enough to need light treatment.
LatakiaAges Up to 1 month - NCT07112703Recruiting
Breathing exercise study for children with thalassemia
This study tests if a breathing exercise device (incentive spirometer) can improve lung function and daily activity in children with thalassemia who receive regular blood transfusions. It aims to help them breathe easier and be more active.
ZagazigAges 6–10 - NCT07107165Recruiting
Support for stem cell transplant patients and caregivers
This study tests a program to help stem cell transplant patients and their family caregivers cope with the stress of treatment. If you are getting a stem cell transplant at the University of Pittsburgh and have a caregiver who can join, you may be able to take part.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07108998RecruitingPhase 2
Epcoritamab as a follow-up treatment for CLL or SLL
This trial tests the drug epcoritamab as a consolidation therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have had a partial response to a second-generation BTK inhibitor (with or without obinutuzumab) but still have detectable disease. The goal is to see if adding this treatment can lead to a deeper response and better outcomes.
Cincinnati, OhioAges 18 years+ - NCT07108530RecruitingPhase 2
Chemotherapy and transplant for adult acute myeloid leukemia
This trial tests a combination of chemotherapy and stem cell transplant for adults with acute myeloid leukemia (AML) that is not a specific subtype called APL. It aims to see if this approach is more effective than standard treatments.
Taiyuan, ShanxiAges 14–65 - NCT06925464RecruitingPhase 1/Phase 2
Modified immune cells for T-cell lymphoma
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 14–70 - NCT06967038RecruitingPhase 1/Phase 2
Natural killer cell therapy for high-risk lymphoma with Sjogren's syndrome
This trial tests a new type of immune cell therapy using natural killer cells to treat people who have both high-risk lymphoma and primary Sjogren's syndrome. The goal is to see if these cells can safely and effectively fight the lymphoma while managing the autoimmune condition.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06967285Recruiting
Prone positioning for ARDS: checking brain blood flow
This trial studies how lying on your stomach (prone positioning) affects blood flow in the brain during severe lung failure (ARDS). It aims to predict and prevent brain problems that might occur with this treatment.
Chengdu, SichuanAges 18 years+ - NCT07102849Enrolling by invitation
Studying bone marrow failure with biospecimens and data
This study analyzes blood, bone marrow, and medical information from people with bone marrow failure syndromes (BMFS) and healthy volunteers to better understand these conditions and find new ways to help patients.
Bethesda, MarylandAges 2–120
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,922 recruiting hematology studies from the U.S. registry right now, out of 7,323 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.